About Neurovance
Neurovance is a company based in Cambridge (United States) founded in 2011 was acquired by Otsuka in March 2017.. Neurovance has raised $53.03 million across 6 funding rounds from investors including Otsuka, Tekla Capital Management and Venture Investors. The company has 7 employees as of December 31, 2016. Neurovance operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Cambridge, United States
- Employees 7 as on 31 Dec, 2016
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Leadership Team
27 people
Data Analysis and Operations Team
24 people
Software Development Team
16 people
Human Resources and Administration
13 people
Operations Team
9 people
Sales and Marketing
8 people
Senior Team
8 people
Legal and Compliance
8 people
Unlock access to complete
Funding Insights of Neurovance
Neurovance has successfully raised a total of $53.03M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $554.28 thousand completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $554,280
-
First Round
First Round
(30 May 2012)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2017 | Amount | Series B - Neurovance | Valuation |
investors |
|
| Dec, 2016 | Amount | Series B - Neurovance | Valuation |
investors |
|
| Jun, 2015 | Amount | Series B - Neurovance | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Neurovance
Neurovance has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Otsuka, Tekla Capital Management and Venture Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neurovance
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Neurovance
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neurovance Comparisons
Competitors of Neurovance
Neurovance operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for central nervous system diseases and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for immunological and neurological disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Neurovance
When was Neurovance founded?
Neurovance was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Where is Neurovance located?
Neurovance is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Neurovance a funded company?
Neurovance is a funded company, having raised a total of $53.03M across 6 funding rounds to date. The company's 1st funding round was a Series B of $26.5M, raised on May 30, 2012.
How many employees does Neurovance have?
As of Dec 31, 2016, the latest employee count at Neurovance is 7.
What does Neurovance do?
Neurovance was established in 2011 in Cambridge, United States, as a clinical-stage company in the neuroscience sector. Centanafadine, a triple reuptake inhibitor targeting norepinephrine, dopamine, and serotonin, is advanced for adult ADHD management. An extended-release formulation of this compound is under development for adolescent and pediatric ADHD to support improvements in attention and executive function.
Who are the top competitors of Neurovance?
Neurovance's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Who are Neurovance's investors?
Neurovance has 6 investors. Key investors include Otsuka, Tekla Capital Management, Venture Investors, GBS, and Novartis Venture Fund.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.